$XENT News

Last published 2y ago

2y agoXENTFDA Roundup: November 5, 2024FDA Press ReleasesToday, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published “Catching Up with Califf: One Health - Optimal Public Health Outcomes for Humans and Animals in Our Shared Environment,” by FDA Commissioner Robert M. Califf, M.D. Dr. Califf discusses One Health and the FDA’s mission to collaborate across disciplines and sector ...
2y agoXENTNew Amsterdam, LLC vs Intersect ENT, Inc. et al. - AIA Trial, Settled Before InstitutionUS Patent Trial and Appeal Board
3y agoXENTApproval of Sinuva, Nda #209310 (Labeling)FDA Approved DrugsApproval Date: 01/20/2023; Drug Name: Sinuva, Nda #209310; Active Ingredients: MOMETASONE FUROATE; Company: Intersect Ent Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 209310
4y agoXENTReal-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource UtilizationBusiness WireData from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18
4y agoOFIX XENTOrthofix Announces Appointment of Thomas A. West to Board of DirectorsBusiness WireOrthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Comm
5y agoXENTIntersect ENT Reports Third Quarter 2021 Financial ResultsBusiness WireIntersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 millio
5y agoXENTFirst Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in EuropeBusiness WireIntersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the U
5y agoANAT SAFM SIC XENTMoore Kuehn Encourages SAFM, ANAT, SIC, and XENT Investors to Contact Law FirmPR NewswireNEW YORK, Aug. 24, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to s
5y agoDIDI GPRO MCFE MGNI+1Thinking about buying stock in Intersect ENT, Magnite, McAfee, DiDi Global, or GoPro?PR NewswireNEW YORK, Aug. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XENT, MGNI, MCFE, DIDI, and GPRO. T
5y agoXENTIntersect ENT Reports Second Quarter 2021 Financial ResultsBusiness WireIntersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview
5y agoMDT XENTMedtronic to Acquire Intersect ENTPR NewswireDUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ:XENT), a global ear, nose, and thro
5y agoXENTU.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT's Continued Commitment to Providing Innovative, Solutions for Patients with Chronic RhinosinusitisBusiness WireVenSure and Cube Join the Company's Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated t
5y agoXENTIntersect ENT to Report Second Quarter 2021 Financial Results on August 6Business WireIntersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021. The Company
5y agoXENTIntersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term LoanBusiness WireIntersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update. Second Quarter 2021 Ove
5y agoMDT SNN XENT IMDC+1Neurent Medical Expands Leadership Team to Support Advancement of In-Office Chronic Rhinitis TreatmentBusiness WireNew Hires Bring Significant ENT and Industry Experience Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced expansions of its leadership team. The hires bring deep medical device i
5y agoXENTIntersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus SurgeryBusiness WireLocalized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient c
5y agoXENTIntersect ENT Reports First Quarter 2021 Financial ResultsBusiness Wire— Increases 2021 Revenue Guidance to $117 Million to $121 Million — Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for th
5y agoXENTIntersect ENT, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 10, 2021 / Intersect ENT, Inc. (NASDAQ:XENT) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 8:30 AM Eastern Time. To listen to the event live or access a
5y agoXENTIntersect ENT to Participate at Upcoming Investor ConferencesBusiness WireIntersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that management will participate in the following upcoming investor conferences: Bank of Amer
5y agoXENTIntersect ENT Announces Appointment of New Vice President of SalesBusiness WireMark L. Alley to serve as Vice President of Sales Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice Pres
5y agoXENTIntersect ENT Announces Date Change for First Quarter 2021 Financial Results AnnouncementBusiness WireIntersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, announced that the Company has changed the date of its previously scheduled first quarter 2021 financial results a
5y agoXENTEXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus DilationBusiness WireStudy Initiates with Registration on ClinicalTrials.gov Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that it began the process of initiati
5y agoXENTIntersect ENT to Report First Quarter 2021 Financial ResultsBusiness WireIntersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that it will release first quarter 2021 financial results on Tuesday, May 4, 2021. The Company exp
5y agoXENTIntersect ENT Announces Changes to its Board of DirectorsBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Anthony Vernon has resigned from the Intersect ENT Board of Directors on March 31, 2021. Mr. Vernon has served on the Intersect ENT Board since 2015 and is resigning to pursue other interests. Subsequen ...
5y agoXENTDr. Neil Hattangadi Joins Intersect ENT’s Board of DirectorsBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced Neil Hattangadi, M.D., M.Sc. joined the Intersect ENT Board of Directors. Dr. Hattangadi will serve as a member of the Nominating and Corporate Governance Committee of the Board.
5y agoXENTIntersect ENT to Participate at the Oppenheimer 31st Annual Healthcare ConferenceBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conferen ...
5y agoXENTIntersect ENT Reports Fourth Quarter and Full Year 2020 Financial ResultsBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the fourth quarter and full year ended December 31, 2020.
5y agoXENTCMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage AdjudicationBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Medicare and Medicaid Services (CMS) published an average selling price (ASP) for the Company’s SINUVA sinus implant, providing predictability, transparency, and confidence of reimburse ...
5y agoXENTIntersect ENT to Report Fourth Quarter and Full Year 2020 Financial ResultsBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release fourth quarter and full year 2020 financial results on Tuesday, March 9, 2021. The Company expects to issue the release at approximately 7:00 a.m. ET and management will host a conferenc ...
5y agoXENTIntersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus ImplantBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant. The combined packaging of the SDS with PROPEL Mini received pre ...
5y agoXENTFDA Authorizes Marketing of Novel Device to Reduce Snoring and Mild Obstructive Sleep Apnea in Patients 18 Years and OlderFDA Press ReleasesToday, the U.S. Food and Drug Administration authorized marketing of a new prescription only device intended to reduce snoring and mild obstructive sleep apnea. Unlike devices used while patients sleep, this is the first device used while awake that is intended to improve tongue muscle function, which in time can help prevent the tongue from collapsing backwards and obstructing the airway during s ...
5y agoXENTIntersect ENT to Participate in Upcoming Investor ConferencesBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in the following upcoming investor conferences:
5y agoXENTIntersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus ImplantBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Medicare and Medicaid Services (CMS) have approved a revised coding application filed by the Company for its family of PROPEL (mometasone furoate) sinus implants used to reduce inflamma ...
5y agoXENTIntersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020Business WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced preliminary fourth quarter 2020 revenue and provided a business update.
5y agoXENTCORRECTING and REPLACING - Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the 39th Annual J.P. Morgan Healthcare Conference. Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will ...
5y agoXENTNew patent granted for: Seismic Based Fracking Fluid DisposalUS Patent Applications (USPTO)
5y agoXENTIntersect ENT Announces New Appointments to Executive Leadership TeamBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today announced the appointments of Patrick Broderick as Executive Vice President, General Counsel (GC) and Corporate Secretary, and Reyna Fernandez as Chief Human Resource Officer (CHRO). Both Mr. Broderick and Ms. Fernandez will begin servi ...
6y agoXENTIntersect ENT to Participate at Upcoming Investor ConferencesBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that management will participate in the following upcoming investor conferences:
6y agoXENTIntersect ENT, Inc.'s (XENT) CEO Tom West on Q3 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoXENTIntersect ENT Reports Third Quarter 2020 Financial ResultsBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the third quarter ended September 30, 2020.
6y agoXENTNew patent granted for: Drug-Coated BalloonUS Patent Applications (USPTO)
6y agoXENTIntersect ENT Announces Preliminary Revenue for Third Quarter of 2020Business WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced preliminary third quarter 2020 revenue and provided a business update.
6y agoXENTNew patent granted for: Generating Specifications for an OrthosisUS Patent Applications (USPTO)
6y agoXENTIntersect ENT to Report Third Quarter 2020 Financial ResultsBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release third quarter 2020 financial results on November 2, 2020. The Company expects to issue the release at approximately 7:00 a.m. ET and management will host a conference call at 8:30 a.m. ET.
6y agoXENTIntersect ENT Closes Acquisition of Fiagon AG Medical TechnologiesBusiness WireMENLO PARK, Calif. & BERLIN--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it closed the previously announced transaction to acquire Fiagon AG Medical Technologies, a leader in electromagnetic surgical navigation solutions, for €60 million in cash.
6y agoXENTIntersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three YearsBusiness WireMENLO PARK, Calif. and BERLIN--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it has entered into an agreement to acquire Fiagon AG Medical Technologies, a leader in electromagnetic surgical navigation solutions, for €60 million in cash. Under the terms of the transaction, Intersect ENT wil ...
6y agoXENTIntersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus ImplantBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today announced that it has executed a pharmacy services agreement with AllianceRx Walgreens Prime for national specialty pharmacy distribution of the Company’s SINUVA® (mometasone furoate) Sinus Implant.
6y agoXENTNew patent application published for: Activating an Alarm If a Living Being Is Present in an Enclosed Space with Ambient Temperature Outside a Safe Temperature RangeUS Patent Applications (USPTO)
6y agoXENTIntersect ENT Reports Second Quarter 2020 Financial ResultsBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the second quarter ended June 30, 2020.
6y agoXENT BSXAlydia Announces $13.9 Million Financing for Innovative Postpartum Hemorrhage Treatment, Appoints Robert Binney as CEO and Colby Holtshouse as COOBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Alydia Health, today announced that the company has raised $13.9 million in a Series C financing led by AXA Investment Managers through its Impact Investing Strategy. Existing investors including Global Health Investment Fund and Avestria Ventures also participated in the round.